Key result
Novel Spirulina-derived peptide TVLYEH lowers blood pressure in vivo via ACE inhibition.
Why the study?
Novel angiotensin I-converting enzyme inhibitory peptides from Spirulina protein hydrolysate were identified and their antihypertensive effect evaluated in vivo.
The novel peptide TVLYEH derived from Spirulina protein hydrolysate demonstrates significant in vivo antihypertensive effects.
Should not change practice; extends preclinical evidence for Spirulina-derived ACE inhibitors but requires human trials.
By combining virtual screening and experimental assay, two angiotensin I-converting enzyme inhibitory peptides, TVLYEH and LQAGGLF, were identified from the protease K hydrolysate of Spirulina protein, and TVLYEH showed significantly antihypertensive effect in vivo .
No takes yet. Share an insight, caveat, or question.
Suo et al. (2022) studied this question. The novel angiotensin I-converting enzyme inhibitory peptide TVLYEH, derived from Spirulina protein hydrolysate, demonstrated a significant antihypertensive effect in vivo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: